Introduction
Introduction of foreign genes into mammalian hematopoietic precursor cells (HPCs) is an important technology that offers a strategy for the modification of hematopoietic stem cells for various therapeutic purposes. Drug resistance gene delivery into HPCs is an approach that has been studied by several groups with a major focus on retroviral or adenoviral transduction of cells with exogenous DNA. [1] [2] [3] The early extensive investigations by Toneguzzo and Keating established the foundations of gene transfer into human hematopoietic cells by electroporation. [4] [5] [6] Thus far, efficient transduction of human CD34 + HPCs has been limited. Electroporation is a well-established, non-chemical, nonviral technique for the delivery of exogenous molecules into cells. 7 By creating transient pores in the membrane, 8 a variety of molecules can be introduced into target cells, including drugs, antibodies, RNA, and DNA. The advantages include: (1) the procedure is more time efficient; (2) results are highly reproducible once the parameters are determined; (3) the potential for exposure to biohazards is minimized compared with viral approaches for gene transduction. In addition, electroporation has the ability to transfer very large DNA, and it does not require + precursor cells, as determined by flow cytometry 48 h after electroporation. The more primitive cells were also found to be EGFP + as determind by subset analysis using Thy1, CD38, AC133 and c-kit conjugated monoclonal antibodies. Methylcellulose assays on electroporated CD34
+ cells yielded 20% ( ± 7%) EGFP + colonies (CFU-GM, BFU-E and CFU-mix) and 22% ( ± 5%) EGFP + long-term colony-initiating cells (LTC-IC). The reporter gene was found to be integrated into the LTC-IC genomic DNA as determined by inverse PCR and DNA sequencing. These results suggest that electroporation has the potential to effectively and stably deliver exogenous genes into human hematopoietic precursor cells. Gene Therapy (2001) 8, 384-390.
additional cell lines. The risk of insertional mutagenesis and unwanted transcription of cellular genes by viral LTR is also greatly reduced.
In order to maintain the full therapeutic potential of gene delivery into HPCs, the primitive state of the target cells expressing the introduced gene must be maintained. This would allow subsequent in vitro or in vivo differentiation of HPCs into a variety of cell types capable of expressing the transferred gene. However, methods of ex vivo stem cell expansion leading to optimal survival, proliferation and self-renewal of the primitive CD34 + HPCs are currently the focus of investigation. 9, 10 This includes culture conditions and combinations of growth factors, typically cytokines or their recombinant form. The effects of cytokine combinations can be complex and multiple, depending on the stage of differentiation of a particular stem cell. 11 Stromal cells 12 or stroma-conditioned media, fibronectin, 13 and endothelial layers 14 are known to play a role in maintaining a primitive state of stem cells. Thrombopoietin (TPO) in various cocktails with the tyrosine kinase receptor ligands, Flt-3 ligand (Flt-3L) and stem cell factor (SCF), are capable of maintaining phenotypic self-renewal of primitive stem cells. [15] [16] [17] [18] In this article, we report on the optimization of electroporation parameters for gene delivery and stable expression of the transgene in selected human CD34 + HPCs. Our focus is on the use of electroporation as a means of gene transduction, that may ultimately find utility in GMP cell preparation for various clinical applications of CD34 + HPCs.
Results
Optimization of culture conditions for CD34 + HPCs We evaluated several different culture conditions and length of culture period in order to increase the percentage of cells in cycle for optimal integration of the transgene following electroporation. Combinations of TPO, SCF, IL-3, Flt-3L, PIXY-321, human serum and stromalconditioned medium were tested (data not shown). The combination of 50 ng/ml TPO, 20 ng/ml SCF and 50 ng/ml Flt-3L was superior to other growth factor combinations in its ability to recruit CD34 + HPCs into cycle, while maintaining primitive progenitor capability. This is consistent with previous reports demonstrating a role for Flt-3L and TPO in stimulating self-renewal of human stem cells.
19 CD34 + HPCs cultured in serum-free culture medium (X-VIVO 10) supplemented with TPO/SCF/Flt-3L for 48 h resulted in 35-40% of the CD34 + cells in S plus G2/M. As shown in Figure 1 , both % CD34
+ cells in S-phase and % EGFP-positive cells increased within 24-48 h in culture with TPO/SCF/Flt-3L. On day 1, 25% of cells were in S-phase and remained at that level or slightly above that level for up to 4 days. The percentage of cells expressing EGFP peaked at day 1 and day 2, then decreased to 14% by day 3 and 7% by day 4. Therefore, CD34
+ cells used in subsequent electroporation experiments were cultured in this medium for 48 h before electroporation. 
Optimization of electroporation parameters for CD34

/CD34
+ cells 48 h after electroporation is shown in Figure 2a (inset), which peaked from 220 V to 240 V.
DNA concentrations between 1 and 50 g/500 l were evaluated as shown in Figure 2b . We observed a steep increase of % EGFP +
+ cells from 1 g/500 l to 10 g/500 l, with a more modest increase between 10 g/500 l and 30 g/500 l CD34 + cells. Further increases in DNA concentration did not result in higher EGFP efficiency. The viability dropped over the same range of DNA concentrations. Based on these results, we used 30 g DNA/500 ml for further studies. CD34 + cells (1 × 10 6 /500 ml) were electroporated with 30 g/500 l of DNA at a voltage of 220 V and a pulse length that varied from 25 ms to 70 ms ( Figure 2c ). The % EGFP + cells averaged higher than 20% for pulse lengths above 24 ms. Since viability decreased at 45 ms or higher, we chose 38 ms as the optimal pulse length.
We also investigated the effects of cell density on the electroporation efficiency and viability of CD34 + cells using the optimal electroporation parameters 220 V (550 V/cm), 38 ms, 30 g DNA/500 l. CD34
+ cells were suspended in 500 l in X-VIVO 10 supplemented with 1% HSA at densities between 0.2 × 10 6 and 10 × 10 6 cells/ml for electroporation. In three separate experiments, we measured 26.4 ± 2.5%, 22.0 ± 3.0% and 23.8 ± 2.6% EGFP
, 2 × 10 6
, and 10 × 10 6 cells/ml, respectively. Thus, within the range tested, cell density did not show significant effects on electroporation efficiency.
Subset analysis of CD34 + cells being transfected As shown in Figure 3 , electroporation using these parameters also resulted in the expression of reporter gene in the more primitive stem cells (approximately 7% of CD34 + cells) as evaluated by subset analysis using AC133, c-kit, Thy1 and CD38-conjugated monoclonal antibodies.
Effect of electroporation on viability and colony-forming ability as measured by CFU and LTC-IC The effect of electroporation on % viability of CD34 + cells transfected with 30 g DNA/500 l as measured 48 h after electroporation was 57% compared with 69% for mock-electroporated and 77% for non-electroporated. To ascertain the effect of electroporation on the ability of cells to form colonies, we compared CFU and LTC-IC of non-electroporated cells, cells electroporated without DNA (mock), and cells electroporated with pEGFP-N1 ( Figure 4) and presence of DNA reduced CFU colony formation to 88% and 56%, respectively, compared with non-electroporated CD34 + cells. In terms of LTC-IC, electroporation in the absence of DNA had no significant effect on colony formation. However, electroporation with DNA reduced LTC-IC to 67% compared with non-electroporated cells.
Electroporation efficiency using optimal conditions
The mean percentages of EGFP + /CD34
+ cells, CFU and LTC-IC from six patient samples using the optimal conditions are 21 ± 1% by flow cytometry, 20 ± 7% by CFU scoring, and 22 ± 6% by LTC-IC CFU scoring, thus demonstrating the potential of our electroporation and culture conditions in introducing DNA into hematopoietic precursor cells. A typical myeloid LTC-IC colony is shown in Figure 5b using a FITC filter. Figure 5a shows the same colony under normal light. Cells in the positive colony appear uniformally fluorescent.
Integration of reporter gene into genomic DNA To determine whether the reporter gene was stably integrated into the genome or expressed episomally in LTC-IC colonies, inverse PCR and sequence determination was performed on purified genomic DNA. The rationale is that if the reporter gene is integrated into the chromosomal DNA, a sequencing primer upstream to the integration site would result in sequences consistant with the parental plasmid pEGFP-N1 sequence at the 5Ј end and sequences consistant with genomic DNA starting from the point where integration is assumed. This is shown in the nucleotide sequence of the inverse PCR product (Figure 6a ) and the sequence using pEGFP-N1 as control template (Figure 6b ). The overall sequence alignment is shown in Figure 6c , demonstrating integration of the plasmid into genomic DNA. 
Discussion
We report here the optimization of electroporation parameters for isolated CD34 + HPCs from mobilized ovarian and breast cancer patients. CD34
+ HPCs were cultured in serum-free culture medium (X-VIVO 10) supplemented with TPO/SCF/Flt-3L for 48 h before electroporation and evaluated 48 h later using flow cytometry. Optimal electroporation conditions consisted of 220 V, 38 ms, 30 g DNA/500 ml. CD34
+ HPCs maintain their CD34 bright expression after 96 h in culture with 21 ± 1% EGFP + /CD34 + . Similar efficiency is measured after 14 days as colony-forming units (20 ± 7%), and after 7 weeks as LTC-IC (22 ± 6%). The 22% LTC-IC efficiency from this study is comparable to that by retroviral vector-mediated transduction. 20, 21 Furthermore, data presented in this report measure human LTC-IC producing the functional gene product. The integration of the introduced DNA Gene Therapy
Figure 6 Nucleotide sequences using cloned inverse PCR product of LTC-IC genomic DNA (a) and pEGFP-N1 plasmid (b) as templates. Integration point is indicated by the arrow. The alignment between the two sequences is shown in panel c.
into LTC-IC demonstrated that the transgene introduced by electroporation is stable.
We observed no difference in transfection efficiencies for selected CD34
+ cells in the range of cell densities we tested (0.2 × 10 6 /ml to 10 × 10 6 /ml). While this may depend on cell type, a previous report demonstrated similar electroporation efficiencies for two human cell lines for concentrations between 1 × 10 6 and 20 × 10 6 cells/ml. 22 In cases where the quantity of CD34 + cells is limited, valid data can be obtained with relatively low cell concentrations. In contrast, when there is a need to electroporate large numbers of cells, such as in clinical applications, great savings on time and supply resources would be possible by using a higher concentration of cells.
It is interesting to note that CD34 + HPCs are relatively tolerant to electrical strength, as evidenced by a lack of significant changes in efficiency and viability with increase in pulse length from 23 to 70 ms. Although the viability began decreasing at 40 ms, the decline leveled off at about 40% of viable cells. Pulse length () is a function of capacitance and resistance, and the resistance of the electroporation system is a function of cell suspension volume in the cuvette. The insensitivity of CD34 + HPCs to pulse length () will be of value when small fluctuations in pipetting are unavoidable, and may be important in a clinical setting where a continuous delivery of cell suspension is followed by controlled pulses.
The introduction of genes by electroporation has been used stably to transfect progenitor cells, lymphoid cell lines, as well as differentiating and fully differentiated 4 these studies did not provide direct evidence that the plasmid was integrated into the host cell genome. Electroporation has been described for other cell types. Using the EGFP gene as a reporter, Van Tendeloo et al 23 recently approached transient efficiencies of 12% for progenitor cell-derived dendritic cells and 16% for progenitor cell-derived Langerhans' cells. It is not clear at this point whether these efficiencies, and those reported in this paper for selected CD34 + HPCs (21%), are the upper limits. In addition, the high efficiency of LTC-IC (22 ± 5%) and demonstration of stable integration achieved in this paper are promising.
The lack of replication origin for human cells on the pEGFP-N1 plasmid, along with the LTC-IC phenotype imply that the reporter gene has stably integrated into the genome. This was further supported by using a proof-reading and high fidelity DNA polymerase for inverse PCR followed by sequencing. Sequence from nucleotide 179 to 475 has been used as a query for BLAST search of various databases including GenBank(nr), htgs and dbEST, with no similar sequences found, indicating that it is not a contaminant vector sequence, and that it should be a human genomic sequence as yet not determined.
This paper focuses on optimizing conditions for high efficiency transfer of DNA into CD34 + stem cells. A major potential utility of our findings is that it can be applied to a closed bag culture system, which is currently part of several clinical trials using T lymphocytes. 24, 25 The electroporator can be placed in-line with the gas permeable bags in which the cells are cultured. By forming an assembly line of CD34 + cell selection, ex vivo expansion, and electroporation in a closed system, stem cell transplantation with gene therapy could experience added simplicity, safety, and efficacy.
Materials and methods
Materials
The ECM 600 electroporator (exponential decay) was from Genetronics (San Diego, CA, USA). The FACScan Cytometer, CellQuest, ModFit LT, the monoclonal antibodies mouse IgG1/PE, HPCA-2 anti-CD34-PE, HPCA-2 anti-CD34-PerCP, anti-CD38-PE were from Becton Dickinson (San Jose, CA, USA). Thy1-PE and c-kit-PE were from BD-Pharmingen (San Diego, CA, USA). Sequence alignment was performed using Lasergene from DNASTAR (Madison, WI, USA). The Miltenyi CD34 isolation kit and separation columns were from Miltenyi Biotec (Auburn, CA, USA). The Isolex 300i CD34 isolation system and CD34 selection reagents were from Nexell Therapeutics (Irvine, CA, USA). The human immunoglobulin solution (Gammagard) and human serum albumin (HSA) were from the Hyland Division of Baxter Healthcare (Glendale, CA, USA). The plasmids pEGFP-N1, pcDNA3, and pGEM T-Easy were purchased from ClonTech Laboratories (Palo Alto, CA, USA), Invitrogen (Carlsbad, CA, USA), and Promega (Madison, WI, USA), respectively. Microcon-PCR filters were from Millipore (Bedford, MA, USA). Dulbecco's phosphate-buffered saline (DPBS, Ca 2+ and Mg 2+ -free), X-VIVO 10 culture medium, and l-glutamine were from BioWhittaker (Walkersville, MD, USA). Stem Cell Factor (SCF) was from R&D Systems (Minneapolis, MN, USA). Flt-3L was kindly provided by Immunex (Seattle, WA, USA). Thrombopoietin (TPO) was from Genzyme (Cambridge, MA, USA) or R&D Systems. MethoCult H4433 and MyeloCult H5100 were from Stem Cell Technologies (Vancouver, BC, Canada). All other medium and biochemicals (including JumpStart REDAccuTaq LA PCR kit) were from Sigma Chemical (St Louis, MO, USA).
CD34
+ cell selection Fresh or cryopreserved peripheral blood apheresis products from ovarian and breast cancer patients treated with mobilization chemotherapy and/or recombinant granulocyte colony-stimulating factor (G-CSF) were used as the source of cells for CD34 + selection. CD34 + cells were selected on the Isolex 300i or the Miltenyi CD34 isolation kit using Midimax and Supermacs separation columns according to the manufacturer's instructions. CD34
+ cell purities were greater than 90% as assessed by flow cytometry after selection. Human blood was obtained in accordance with institution and federal guidelines for the use of human tissue.
Culture conditions for CD34
+ cells CD34 + cells were initiated at 5 × 10 5 cells/ml in 'complete' medium of X-VIVO 10 supplemented with 2 mm of fresh l-glutamine and the following recombinant human growth factors: 50 ng/ml Flt-3L, 20 ng/ml stem cell factor (SCF), and 50 ng/ml TPO.
Cell cycle analysis Cells (5 × 10 5 ) were flash-spun in an Eppendorf microcentrifuge. The pellet was washed once in DPBS and resuspended in 0.5 ml hypotonic propidium iodide solution (1.0 mg/ml sodium citrate, 0.05 mg/ml propidium iodide, 0.1% Triton X-100, 0.1 mg/ml RNase). The suspension was then placed on ice for 20 min before nuclei analysis by flow cytometry. The samples were collected on day 0 and day 2 of culture on FL-2A (linear) histograms using CellQuest with low-speed data acquisition of 10 000 total events. Analysis was performed using the ModFit LT software. For the time-course of S-phase and electroporation experiments, aliquots of cells were analyzed for S-phase and electroporated, and the expression of EGFP was evaluated by flow cytometry 48 h after electroporation.
Electroporation optimization
Immediately before electroporation, cells were pelleted by centrifugation for 10 min at 250 g at room temperature and resuspended at 2 × 10 6 viable cells/ml in electroporation buffer (X-VIVO 10 supplemented with 1.0% HSA). The plasmids pEGFP-N1 (2 g/l) or pcDNA3 (2 g/l, control) in sterile DPBS were added to 4-mm gap sterile disposable electroporation cuvettes, followed by addition of 500 l cell suspension (1 × 10 6 cells). The cell-DNA mixtures were electroporated and immediately added to 2 ml of complete medium in 24-well plates and incubated at 37°C, 5% CO 2 for an additional 48 h. To optimize electroporation conditions, all parameters except one were fixed for each experiment. These parameters were 220 V (550 V/cm), 1600 F (38 ms), 30 g DNA, 1.0 × 10 6 cells in 500 l of X-VIVO 10 supplemented with 1% HSA at ambient temperature.
Determination of transfection efficiency by flow cytometry
The EGFP gene carried on the pEGFP-N1 plasmid encodes a red-shifted variant of GFP optimized for brighter fluorescence and higher expression in mammalian cells. 26 The EGFP protein produced by the introduced DNA in the cell is fluorescent (excitation: 488 nm, emission: 513 nm), thus the efficiency of electroporation can be monitored by fluorescent microscopy or flow cytometry. Forty-eight hours after electroporation, CD34
+ cells (1 × 10 5 -5 × 10 5 cells) were washed in DPBS with 0.5% bovine serum albumin, and incubated with 20 l of anti-CD34-PE monoclonal antibody for 30 min on ice. The cells were then washed and resuspended in 1 ml of DPBS with 0.5% bovine serum albumin. Propidium iodide was added at 10 g/ml to each tube immediately before flow acquisition. Percent viable cells were determined by gating on propidium iodide-negative cells and the gated viable CD34
+ cells were then evaluated on a dot plot displaying FL1 (EGFP) and FL2 (CD34-PE). Subset evaluation was done using flow cytometry on gated CD34 PerCP + cells.
Colony-forming unit (CFU) assay
Forty-eight hours after electroporation, CD34 + cells from various electroporation parameters (and non-electroporated CD34
+ cells) were plated in duplicate CFU dishes at a density of 5000 cells per 35-mm dish in 1 ml of MethoCult H4433. The CFU assays were scored after 14 days incubation at 37°C, 5% CO 2 for CFU-granulocyte-macrophage (CFU-GM), burst forming-unit erythroid (BFU-E), and mixed (CFU-Mix) colonies. EGFP-positive colonies were scored on an inverted fluorescent microscope and cloning efficiencies determined based on the number of EGFP-positive colonies relative to the total number of colonies counted.
Long-term colony-initiating cell (LTC-IC) assay
Forty-eight hours after electroporation, CD34
+ cells were plated at 1 × 10 5 cells per well on pre-formed irradiated (25 Gy) allogeneic bone marrow stroma in 24-well plates in 2 ml of MyeloCult H5100 supplemented with 0.2 ng/ml hydrocortisone. Non-electroporated cells were plated at 2 × 10 4 cells per well. Plates were incubated at 33°C, 5% CO 2 for 5-6 weeks. At weekly intervals half the culture volume was removed above the adherent cell layer and replaced with fresh culture medium. At the end of the culture period the supernatant was removed, and cells were trypsinized by rinsing with DPBS before adding 200 l of 0.05% trypsin/0.53 mm EDTA solution. Adherent cells were combined with the culture supernatant and centrifuged at 250 g for 10 min. The total cells from each well were then plated into CFU assays as described above and scored after 14 days. EGFP-positive colonies and cloning efficiencies were determined as described above.
Inverse PCR and sequence determination of genomic DNA from LTC-IC Cells from the LTC-IC plates were pelleted and genomic DNA extracted using the Qiagen DNeasy tissue kit Gene Therapy (Valencia, CA, USA). Long inverse PCR was then performed based on Raponi et al, 27 with modifications. Briefly, 2 g of the genomic DNA was digested with 200 units each of BamHI and BglII in 500 l volume at 37°C for 3 h followed by heat inactivation at 80°C for 20 min. Digested DNA was then concentrated with Microcon into 20 l followed by self ligation in 800 l volume at 15°C for 16 h. The ligation reaction was again concentrated with Microcon into 50 l and 1 l was used in a 50 l inverse PCR reaction containing 2.5 units of JumpStart REDAccuTaq DNA Polymerase LA, 1 × buffer (50 mm Tris-HCl, 15 mm ammonium sulfate (pH 9.3), 2.5 mm MgCl 2 , 0.1% Tween 20), 500 m each dNTP, and 0.2 m each of 5Ј-GTGAACTTCAAGATCCGCCACAACATCGAGGAC-3Ј (upper) and 5Ј-TCCTTGAAGAAGATGGTGCGCTCC TGGACGTAG-3Ј (lower) as primers. Thermocycling parameters were 94°C for 30 s followed by 30 cycles of 94°C for 15 s and 68°C for 15 min. A 5 s increment/cycle was programmed into the last 15 cycles to compensate for the potential polymerase activity decrease. The inverse PCR product was cloned into pGEM-T/E. coli and the DNA sequence was determined on a PE Biosystems Prism 377XL automated DNA sequencer.
